InVivo Therapeutics Holdings Performance
| NVIVDelisted Stock | USD 0.32 0.09 21.95% |
On a scale of 0 to 100, InVivo Therapeutics holds a performance score of 1. The company retains a Market Volatility (i.e., Beta) of 1.29, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, InVivo Therapeutics will likely underperform. Please check InVivo Therapeutics' semi variance, as well as the relationship between the rate of daily change and relative strength index , to make a quick decision on whether InVivo Therapeutics' current trending patterns will revert.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in InVivo Therapeutics Holdings are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak forward indicators, InVivo Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 10.7 M |
InVivo |
InVivo Therapeutics Relative Risk vs. Return Landscape
If you would invest 68.00 in InVivo Therapeutics Holdings on January 26, 2024 and sell it today you would lose (36.00) from holding InVivo Therapeutics Holdings or give up 52.94% of portfolio value over 90 days. InVivo Therapeutics Holdings is currently generating 0.9595% in daily expected returns and assumes 45.6743% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than InVivo, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
InVivo Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for InVivo Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as InVivo Therapeutics Holdings, and traders can use it to determine the average amount a InVivo Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.021
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NVIV | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 45.67 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.96 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average InVivo Therapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of InVivo Therapeutics by adding it to a well-diversified portfolio.
InVivo Therapeutics Fundamentals Growth
InVivo Stock prices reflect investors' perceptions of the future prospects and financial health of InVivo Therapeutics, and InVivo Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on InVivo Stock performance.
| Return On Equity | -0.98 | |||
| Return On Asset | -0.54 | |||
| Current Valuation | (7.59 M) | |||
| Shares Outstanding | 3.11 M | |||
| Price To Earning | (1.90) X | |||
| Price To Book | 0.1 X | |||
| EBITDA | (9.8 M) | |||
| Cash And Equivalents | 13.03 M | |||
| Cash Per Share | 9.36 X | |||
| Total Debt | 949 K | |||
| Debt To Equity | 0.09 % | |||
| Book Value Per Share | 2.87 X | |||
| Cash Flow From Operations | (10.13 M) | |||
| Earnings Per Share | (3.28) X | |||
| Total Asset | 18.82 M | |||
| Retained Earnings | (248.62 M) | |||
| Current Asset | 20.74 M | |||
| Current Liabilities | 3.31 M | |||
About InVivo Therapeutics Performance
To evaluate InVivo Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when InVivo Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare InVivo Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand InVivo Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents InVivo's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries . The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. Invivo Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.Things to note about InVivo Therapeutics performance evaluation
Checking the ongoing alerts about InVivo Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for InVivo Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| InVivo Therapeutics is not yet fully synchronised with the market data | |
| InVivo Therapeutics is way too risky over 90 days horizon | |
| InVivo Therapeutics has some characteristics of a very speculative penny stock | |
| InVivo Therapeutics appears to be risky and price may revert if volatility continues | |
| InVivo Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (9.33 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| InVivo Therapeutics Holdings currently holds about 13.03 M in cash with (10.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.36, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing InVivo Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether InVivo Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining InVivo Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating InVivo Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of InVivo Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of InVivo Therapeutics' stock. These opinions can provide insight into InVivo Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in InVivo Stock
If you are still planning to invest in InVivo Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the InVivo Therapeutics' history and understand the potential risks before investing.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |